Patents Assigned to Quest Diagnostics Investments LLC
  • Patent number: 10494629
    Abstract: The invention provides methods for isolating RNA from the soluble fraction of urine. The methods can be used for detecting the presence or absence of an RNA, or quantifying the amount of an RNA. The methods are useful for diagnosing an individual suspected of having a disease by detecting the level of RNA associated with the disease in the soluble fraction of urine. The methods are also useful for prognosing an individual diagnosed with a disease by detecting the level of RNA associated with the disease in the soluble fraction of urine.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: December 3, 2019
    Assignee: Quest Diagnostics Investments LLC
    Inventors: Heather Sanders, Hai-Rong Li
  • Publication number: 20190330704
    Abstract: The present technology provides polynucleotide compositions and methods of using the same to detect circulating tumor DNA (ctDNA) in a patient. Kits for use in practicing the methods are also provided.
    Type: Application
    Filed: December 27, 2017
    Publication date: October 31, 2019
    Applicant: Quest Diagnostics Investments LLC
    Inventors: Suzzette Arnal, Taraneh Angeloni
  • Publication number: 20190302095
    Abstract: Methods are described for determining the amount of insulin in a sample. Provided herein are mass spectrometric methods for detecting and quantifying insulin and C-peptide in a biological sample utilizing enrichment and/or purification methods coupled with tandem mass spectrometric or high resolution/high accuracy mass spectrometric techniques. Also provided herein are mass spectrometric methods for detecting and quantifying insulin and b-chain in a biological sample utilizing enrichment and/or purification methods coupled with tandem mass spectrometric or high resolution/high accuracy mass spectrometric technique.
    Type: Application
    Filed: June 17, 2019
    Publication date: October 3, 2019
    Applicant: Quest Diagnostics Investments LLC
    Inventors: Stephen W. TAYLOR, Michael McPHAUL, Richard E. REITZ, Zhaohui CHEN, Nigel CLARKE
  • Publication number: 20190285654
    Abstract: Provided herein are methods for high throughput quantitation of testosterone utilizing at least two different derivatizing agents of different masses. In another aspect, provided herein are methods for determining the amount of testosterone in each of a plurality of human samples with a single mass spectrometric assay by subjecting each of a plurality of human samples to a different derivatizing agent to generate a differently derivatized testosterone in each of the plurality of samples; combining the plurality of samples to form a multiplex sample; and quantifying the amount of testosterone in each sample by mass spectrometry.
    Type: Application
    Filed: March 15, 2019
    Publication date: September 19, 2019
    Applicant: Quest Diagnostics Investments LLC
    Inventors: Mildred M. Goldman, Scott Goldman, Juliet Coletti, Nigel Clarke
  • Publication number: 20190284639
    Abstract: The present disclosure provides rapid and non-invasive methods for determining whether a patient exhibiting cancer symptoms, or at risk for hereditary cancers such as breast cancer, ovarian cancer, colon cancer, or skin cancer, will benefit from treatment with one or more therapeutic agents. These methods are based on detecting hereditary cancer-related mutations in small-volume dried biological fluid samples that are collected using a volumetric absorptive microsampling device (e.g., MITRA Tip). Kits for use in practicing the methods are also provided.
    Type: Application
    Filed: November 13, 2017
    Publication date: September 19, 2019
    Applicant: Quest Diagnostics Investments LLC
    Inventors: Heather Sanders, Nigel J. Clarke
  • Publication number: 20190285594
    Abstract: Provided are methods for detecting chromogranin A by mass spectrometry. In another aspect, provided herein are methods for quantitating chromogranin A by mass spectrometry. In another aspect, provided herein are methods for prognosis of or measuring the size of neuroendocrine tumors by mass spectrometry.
    Type: Application
    Filed: March 15, 2019
    Publication date: September 19, 2019
    Applicant: Quest Diagnostics Investments LLC
    Inventors: Darren Weber, Michael Caufield, Michael McPhaul, Scott Goldman, Nigel Clarke
  • Publication number: 20190276904
    Abstract: The present disclosure provides rapid and non-invasive methods for determining whether a patient will benefit from treatment with therapeutic agents that inhibit Hepatitis C virus (HCV). These methods are based on detecting HCV RNA and/or anti-HCV antibodies in small-volume dried biological fluid samples that are collected using a microsampling device. Kits for use in practicing the methods are also provided.
    Type: Application
    Filed: November 13, 2017
    Publication date: September 12, 2019
    Applicant: Quest Diagnostics Investments LLC
    Inventors: Amy Rogers, John Leake, Nigel J. Clarke, Russell E. Baumann
  • Publication number: 20190211408
    Abstract: The present disclosure provides methods and compositions for determining whether a patient exhibiting acute gastroenteritis will benefit from treatment with therapeutic agents that inhibit Norovirus genogroup I (GI) or Norovirus genogroup II (GII). The methods disclosed herein are based on detecting Norovirus genogroup I (GI) and Norovirus genogroup II (GII) in a stool sample without extracting viral nucleic acids from a clinical specimen prior to performing real-time reverse transcription PCR. Kits for use in practicing the methods are also provided.
    Type: Application
    Filed: June 2, 2017
    Publication date: July 11, 2019
    Applicant: Quest Diagnostics Investments LLC
    Inventors: Peter Lee, Raymond Huang, Kristin Ramos, Jules Chen, Michelle Tabb
  • Publication number: 20190206666
    Abstract: Provided are methods for determining the apolipoprotein E (ApoE) phenotype in a sample by mass spectrometry; wherein the ApoE allele(s) present in the sample is determined from the identity of the ions detected by mass spectrometry. In another aspect, provided herein are methods for diagnosis or prognosis of Alzheimer's disease or dementia.
    Type: Application
    Filed: July 31, 2018
    Publication date: July 4, 2019
    Applicant: Quest Diagnostics Investments LLC
    Inventors: Darren Weber, Nigel Clarke
  • Patent number: 10324082
    Abstract: Methods are described for determining the amount of insulin in a sample. Provided herein are mass spectrometric methods for detecting and quantifying insulin and C-peptide in a biological sample utilizing enrichment and/or purification methods coupled with tandem mass spectrometric or high resolution/high accuracy mass spectrometric techniques. Also provided herein are mass spectrometric methods for detecting and quantifying insulin and b-chain in a biological sample utilizing enrichment and/or purification methods coupled with tandem mass spectrometric or high resolution/high accuracy mass spectrometric techniques.
    Type: Grant
    Filed: March 2, 2016
    Date of Patent: June 18, 2019
    Assignee: Quest Diagnostics Investments LLC
    Inventors: Stephen W. Taylor, Michael McPhaul, Richard E. Reitz, Zhaohui Chen, Nigel Clarke
  • Publication number: 20190177801
    Abstract: Described herein are methods for diagnosing melanoma or basal cell carcinoma based on mutations in the DDR2 gene. Further, a distinct subgroup of BRAF-mutated melanomas have somatic mutations in the DDR2 gene as well. Applications of this finding to routine diagnostics include the molecular stratification of melanoma, and the tissue identification of targetable DDR2 kinase mutations in routine formalin-fixed paraffin-embedded sections. Described herein are methods, compositions and kits related to the discovery that DDR2 mutations may be markers for melanoma generally, and BRAF-mediated melanoma in particular, opening up the possibility of dual therapy for melanoma by targeting both DDR2 and BRAF.
    Type: Application
    Filed: December 17, 2018
    Publication date: June 13, 2019
    Applicant: QUEST DIAGNOSTICS INVESTMENTS LLC
    Inventors: Daniel M. Jones, Yongbao Wang, Shere Billouin-Frazier, Justin Windham
  • Publication number: 20190177797
    Abstract: The present invention relates to methods for amplifying various regions of the cystic fibrosis transmembrane regulator (CFTR) gene. Methods are provided for amplifying one or all 27 exons of the CFTR gene and a portion of the CFTR promoter region in a single tube. The method can identify the presence or absence of CF deletions or insertions in a sample and assist in the diagnosis of a genetic predisposition to cystic fibrosis.
    Type: Application
    Filed: December 17, 2018
    Publication date: June 13, 2019
    Applicant: Quest Diagnostics Investments LLC
    Inventors: Feras Hantash, Weimin Sun
  • Publication number: 20190177805
    Abstract: The present technology relates to methods for excluding Lynch syndrome as a possible diagnosis in patients suffering from colorectal cancers or endometrial cancers. These methods are based on detecting the methylation status of the MLH1 promoter ā€˜Cā€™ region in colorectal and endometrial cancer patients using an improved and highly sensitive methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) assay.
    Type: Application
    Filed: August 9, 2017
    Publication date: June 13, 2019
    Applicant: Quest Diagnostics Investments LLC
    Inventors: Kevin Qu, Feras Hantash, Amber Donahue
  • Patent number: 10316372
    Abstract: Provided herein are methods for determining the presence or absence of an enteroviruses and parechoviruses in a biological sample. The methods involve identifying the presence or absence of a target nucleic acids from the viruses using direct amplification from a biological sample without a step of extraction of the nucleic acids, but retaining substantially the same specificity and sensitivity of methods assaying extracted nucleic acids. Also provided are methods of diagnosis using the methods provided and compositions and kits for the practice of the methods.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: June 11, 2019
    Assignee: QUEST DIAGNOSTICS INVESTMENTS LLC
    Inventors: Peter Lee, Lakshmi Nair, Albert Castro, Maria Vestal, Michelle Tabb
  • Publication number: 20190170711
    Abstract: Provided are methods for detecting or determining the amount of guanidinoacetate (GAA), creatine, and creatinine by mass spectrometry.
    Type: Application
    Filed: August 6, 2018
    Publication date: June 6, 2019
    Applicant: Quest Diagnostics Investments LLC
    Inventor: Thomas C. Lynn
  • Publication number: 20190112657
    Abstract: Described herein are methods, compositions and kits directed to amplification of nucleic acids suitable for both next generation sequencing (NGS) and a second round of sequencing as validation, such as Sanger sequencing.
    Type: Application
    Filed: October 26, 2018
    Publication date: April 18, 2019
    Applicant: Quest Diagnostics Investments LLC
    Inventors: Heather Sanders, Hai-Rong Li, Feras Hantash, Frederic Waldman
  • Publication number: 20190112653
    Abstract: The present technology relates to methods for determining whether a patient having thyroid nodules with indeterminate cytology will benefit from diagnostic surgery, e.g., lobectomy. These methods are based on screening a patient's thyroid nodules and detecting alterations in target nucleic acid sequences corresponding to a specific set of thyroid cancer-related genes. Kits for use in practicing the methods are also provided.
    Type: Application
    Filed: December 30, 2016
    Publication date: April 18, 2019
    Applicant: Quest Diagnostics Investments LLC
    Inventors: Shih-Min CHENG, Joseph J. CATANESE, Andrew GRUPE, Feras HANTASH, Frederic M. WALDMAN, Kevin QU
  • Publication number: 20190112662
    Abstract: Truncation variants of BCR-ABL mRNA that produces BCR-ABL proteins with a truncated C-terminus and its role in resistance to treatment with kinase inhibitors is described. Vectors for expressing the truncated gene products are described as well as recombinant cells that express the truncated gene products from cDNA constructs. Also provided are methods compositions and kits for detecting the BCR-ABL truncation variants. Also provided are methods for determining the prognosis of a patient diagnosed as having myeloproliferative disease, and methods for predicting the likelihood for resistance to a treatment with tyrosine kinase inhibitor in a patient diagnosed as having myeloproliferative disease. Additionally, methods for screening BCR-ABL tyrosine kinase domain inhibitors which rely on the recombinant cells are also disclosed.
    Type: Application
    Filed: October 5, 2018
    Publication date: April 18, 2019
    Applicant: Quest Diagnostics Investments LLC
    Inventors: Maher Albitar, Wanlong Ma
  • Publication number: 20190107536
    Abstract: Provided are methods for diagnosing a disease in a subject with a previous streptococcal infection by determining the presence or absence of one or more autoantibodies in a biological sample from the subject, wherein the one or more autoantibodies recognize an antigen from a protein selected from the group consisting of ELAVL2, ELAVL3, ELAVL4, Nova-1, Nova-2, Cdr1, Cdr2; and Cdr3. The presence of such autoantibodies is indicative of a positive diagosis for a post-streptococcal disease such as PANDAS, post-GABHS glomerulonephritis, rheumatic fever, autism and Syndenham's chorea.
    Type: Application
    Filed: December 4, 2018
    Publication date: April 11, 2019
    Applicant: I Quest Diagnostics Investments LLC
    Inventors: Stanley J. Naides, Joanna Popov
  • Publication number: 20190100808
    Abstract: Provided herein are methods and compositions for detection of a nucleic acid target in a sample. The methods and compositions use primer directed amplification in conjunction with nucleic acid fragmentation. The methods have high sensitivity even in the presence of a large amount of non-target nucleic acid. Also provided are oligonucleotides and kits useful in the method. Exemplary nucleic acid targets are those with mutant gene sequence such as mutant sequence of the EGFR, APC, TMPRSS2, ERG and ETV1 genes.
    Type: Application
    Filed: October 19, 2018
    Publication date: April 4, 2019
    Applicant: Quest Diagnostics Investments LLC
    Inventors: Heather R. Sanders, Kevin Z. Qu, Charles M. Strom, Richard A. Bender